Agilent Technologies Adds sub-2-μm Protein Analysis Biocolumns with C3, Diphenyl Phases for Broader Selectivity, Better Peak Shape

Agilent Technologies, Inc has expanded its family of sub-2-μm particle 300 Angstrom pore columns for reversed phase liquid chromatography with ZORBAX RRHD 300SB-C3 and 300-Diphenyl 1.8 μm columns. The columns extend the benefits of reversed-phase biomolecule separations to ultra-high-performance liquid chromatography (UHPLC). The C3 phase broadens the selectivity and improves peak shape and recovery options for larger proteins, including antibodies. The diphenyl phase offers additional selectivity through pi-pi interactions with aromatic amino acids in the primary structure.

“Agilent now offers the broadest range of sub-2-μm, wide-pore biocolumns for reversed-phase liquid chromatography,” said Agilent Product Manager, Linda Lloyd. “The new 1.8 μm columns add to the scalability of the ZORBAX family of C18, C8 and C3 phases available already available with 3.5 and 5 μm particles. We’re pleased to bring this higher order characterisation and increased speed to UHPLC users.”

The 1.8 μm particle size and 300  Angstrom pore size brings UHPLC efficiency, resolution and robust quantitation to reversed-phase protein separations. Additionally, the columns are stable up to 1,200 bar. Agilent’s proven StableBond technology for the C18, C8 and C3, and the end-capped diphenyl with Pursuit chemistry, deliver symmetrical peaks - even at low pH - when using trifluoroacetic or formic acid mobile phase modifiers, without compromising column life. For more information, visit: www.agilent.com/chem/biohplcproteins